Life Science Invest Fund invests in Newbury Pharmaceuticals AB

LSIF has accepted an invitation to participate in a directed issue in Newbury Pharmaceuticals AB. This is our 9th major investment, and we view Newbury Pharmaceuticals AB as a very good fit in our portfolio strategy.
Newbury Pharmaceuticals AB is well into the commercial phase and is rapidly expanding its business with bringing licensed drugs to the market and by entering new markets. For this expansion, the company needs additional capital, and at LSIF we are convinced that this journey has the potential to lead to a substantially higher valuation.

See today's press release here
Our 10th investment will be announced tomorrow.